CANNELLA, LAURA
CANNELLA, LAURA
DIPARTIMENTO DI BIOTECNOLOGIE CELLULARI ED EMATOLOGIA (attivo dal 01/01/1900 al 01/11/2018)
Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?
2015 Cannella, Laura; Caocci, Giovanni; Jacobs, Marc; Vignetti, Marco; Mandelli, Franco; Efficace, Fabio
Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients
2019 Baron, Frédéric; Efficace, Fabio; Cannella, Laura; Willemze, Roel; Vignetti, Marco; Muus, Petra; Marie, Jean-Pierre; Ferrero, Dario; Fazi, Paola; La Sala, Edoardo; Bourhis, Jean-Henri; Fabbiano, Francesco; Bosi, Alberto; Sborgia, Marco; Martinelli, Giovanni; Wittnebel, Sebastian; Trisolini, Silvia; Petti, Maria Concetta; Halkes, Constantijn J M; van der Velden, Walter J F M; de Witte, Theo; Amadori, Sergio; Zittoun, Robert A; Suciu, Stefan
Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
2017 Breccia, Massimo; Baccarani, Michele; Rosti, Gianantonio; Cottone, Francesco; Cannella, Laura; Guilhot, François; Vignetti, Marco; Efficace, Fabio
The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial
2025 Efficace, Fabio; Cannella, Laura; Capodanno, Isabella; Sancetta, Rosaria; Porcu, Veronica; Lunghi, Monia; Biagi, Annalisa; Castagnetti, Fausto; Caocci, Giovanni; Baldi, Thomas; Marasca, Roberto; Bonifacio, Massimiliano; Gozzini, Antonella; Martino, Bruno; Sora, Federica; Westerweel, Peter E.; Fazi, Paola; Vignetti, Marco; Pane, Fabrizio; Breccia, Massimo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned? | 2015 | Cannella, Laura; Caocci, Giovanni; Jacobs, Marc; Vignetti, Marco; Mandelli, Franco; Efficace, Fabio | |
| Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients | 2019 | Baron, Frédéric; Efficace, Fabio; Cannella, Laura; Willemze, Roel; Vignetti, Marco; Muus, Petra; Marie, Jean-Pierre; Ferrero, Dario; Fazi, Paola; La Sala, Edoardo; Bourhis, Jean-Henri; Fabbiano, Francesco; Bosi, Alberto; Sborgia, Marco; Martinelli, Giovanni; Wittnebel, Sebastian; Trisolini, Silvia; Petti, Maria Concetta; Halkes, Constantijn J M; van der Velden, Walter J F M; de Witte, Theo; Amadori, Sergio; Zittoun, Robert A; Suciu, Stefan | |
| Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients | 2017 | Breccia, Massimo; Baccarani, Michele; Rosti, Gianantonio; Cottone, Francesco; Cannella, Laura; Guilhot, François; Vignetti, Marco; Efficace, Fabio | |
| The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial | 2025 | Efficace, Fabio; Cannella, Laura; Capodanno, Isabella; Sancetta, Rosaria; Porcu, Veronica; Lunghi, Monia; Biagi, Annalisa; Castagnetti, Fausto; Caocci, Giovanni; Baldi, Thomas; Marasca, Roberto; Bonifacio, Massimiliano; Gozzini, Antonella; Martino, Bruno; Sora, Federica; Westerweel, Peter E.; Fazi, Paola; Vignetti, Marco; Pane, Fabrizio; Breccia, Massimo |